Divisadero Street Capital Management LP Boosts Stock Position in MiMedx Group, Inc $MDXG

Divisadero Street Capital Management LP lifted its position in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 362.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 223,220 shares of the company’s stock after buying an additional 175,000 shares during the period. Divisadero Street Capital Management LP owned about 0.15% of MiMedx Group worth $1,364,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in MiMedx Group in the second quarter worth approximately $2,317,000. Trigran Investments Inc. lifted its holdings in shares of MiMedx Group by 10.4% in the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock worth $51,266,000 after acquiring an additional 790,901 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of MiMedx Group by 11.3% in the 2nd quarter. First Trust Advisors LP now owns 353,455 shares of the company’s stock valued at $2,160,000 after purchasing an additional 35,872 shares in the last quarter. Invesco Ltd. grew its holdings in shares of MiMedx Group by 8.6% during the 2nd quarter. Invesco Ltd. now owns 82,659 shares of the company’s stock valued at $505,000 after purchasing an additional 6,536 shares during the last quarter. Finally, Isthmus Partners LLC grew its holdings in shares of MiMedx Group by 26.2% during the 2nd quarter. Isthmus Partners LLC now owns 391,484 shares of the company’s stock valued at $2,392,000 after purchasing an additional 81,222 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

Insider Transactions at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 58,300 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total value of $432,586.00. Following the completion of the transaction, the insider directly owned 236,982 shares in the company, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.70% of the company’s stock.

MiMedx Group Trading Up 1.0%

Shares of MDXG opened at $6.93 on Monday. The stock has a market capitalization of $1.03 billion, a P/E ratio of 25.67 and a beta of 1.64. MiMedx Group, Inc has a twelve month low of $5.79 and a twelve month high of $10.14. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. The firm has a fifty day simple moving average of $7.00 and a two-hundred day simple moving average of $6.83.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Monday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $67.69 million during the quarter. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%. On average, research analysts anticipate that MiMedx Group, Inc will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of MiMedx Group in a report on Tuesday, November 25th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, MiMedx Group has an average rating of “Moderate Buy” and an average target price of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.